Scientists of the largest drug makers are being pushed by the governments of the largest countries to develop a vaccine to put an end to the latest coronavirus.
The goal in the US is to have a vaccine ready for at least some use by year end. Given the stringent approval process by the US FDA, it could be safe to say that another country may beat us to it. China and Russia have both made claims to this effect. But how safe will they be? Will there be any lasting side effects?
BioPharmaDive.com just released an interactive table which illustrates the progress of the top biotechnology companies in a race to a Covid-19 Vaccine.
It’s showing Moderna (NASDAQ: MRNA) as an initial leader, but Sanofi with GlaxoSmithKline (NYSE: GSK) with the most progress, and a first available supply potentially in January 2021.
Novavax (NASDAQ: NVAX) however is showing they will be the first to start a late stage study.
Have a look at the table, you can find it here.
Here is a sleeper you may want to look at while we are waiting for a vaccine.
Take a look at Glucose Health, Inc. (OTC Pink: GLUC). Glucose Health manufacturers nutritional beverages for the diabetic-adult nutrition consumer retail category under the registered trademark GLUCODOWN®.
Now…more than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report released by the Centers for Disease Control and Prevention (CDC).
Here is a company in the space that is finding its way onto the shelves of some major pharmacy retailers including Walmart (NYSE: WMT), CVS Health (NYSE: CVS) and online at Amazon.com (NASDAQ: AMZN) yet is still trading below a $30 million valuation.
GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain healthy blood sugar levels and regular digestive health.
Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.
What are the revenues of this company going to look like when the latest GLUCODOWN® numbers are reported for Q3 and Q4?
Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetes space and should be on everybody’s watch list.
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.